Unephra is an investigational device preparing for its first clinical pilot Q4 2026. Health systems can request early access to the device and care-team dashboard.
Keeping Heart Failure Patients Home
Lab-in-Bathroom. Passive at-home urine monitoring that flags early signs of fluid and sodium imbalance, so care teams can step in days before a decompensation turns into a readmission.
• Non-invasive, no patient effort: works during normal bathroom use
• Multi-user household support with authentication
• Insights shared between patients and their care team
Important: Unephra is a Non-Significant Risk (NSR) investigational device, not yet cleared by FDA.
Supported by
and
About
Heart failure is one of the leading drivers of hospital readmissions. Many of those readmissions follow fluid and sodium changes that build quietly at home. Unephra turns everyday bathroom visits into cardio-renal insights on the patient’s own physiology. Care teams can adjust treatment early, and patients can stay home and out of the hospital.
Our Mission
Reduce avoidable heart failure readmissions by bringing personalized cardio-renal monitoring into the home
Our Focus
Post-discharge and at-home management for heart failure and hypertensive patients
Our Goal
Earlier intervention, fewer readmissions, lower cost of care
Our Vision
A Future Where Personalized Health is More Accessible, Effortless and Effective
Our Values
Innovation, Quality, and Customer & User Centric Design
How Unephra Works
Fluid and sodium imbalance often builds up days before symptoms of heart failures starts to appear. Unephra's sensing technology enables early detection increased risk factors associated with changes in medication and dietary patterns.
Sense
Passive in-toilet measurement
A micro-sensor array measures urine output, sodium and potassium concentrations
automatically during normal use. No strips, no wearables, nothing for the patient to remember. Household members are recognized and kept separate by authentication.
Analyze
Personalized cardiorenal baseline
Unephra learns each patient’s own baseline and uses a cardio-renal physiological model to flag meaningful changes in sodium and fluid status, rather than comparing against population averages.
Intervene
Alerts the care team's workflow
Trends and alerts reach a care-team dashboard with elevated risks marked and possible root cause identified, so clinicians can check with the patient and adjust diuretics or diet as necessay before a decompensation becomes a readmission.
Care team can see patient's adherence and verify the outcome of the intervention.
Ecosystem
Programs & Collaborations
Permanente Medicine
Following the Techstars Healthcare Accelerator powered by Permanente Medicine (2025), Unephra is preparing a clinical pilot with MAPMG. Status: SOW & Protocol reviewed and approved (9/25/2026). Pilot details available to investors on request.
Snyder Lab | Stanford
Unephra plans to participate in iPOP (Integrated Personal Omics Profiling) program, which is running at Snyder Lab, Stanford, by providing longitudinal cardiorenal physiology data.
KeborMed
Unephra's cloud solution is built on Kubyk, the connected health platform from KeborMed Inc., designed for regulated healthcare environments, supporting HIPAA compliance, ISO 13485 and ISO 27001 frameworks, Single Sign-On (SSO), and FHIR-compatible interoperability with healthcare systems and EHR workflows.
